CN102844029A - 用于治疗听力损伤和眩晕的β-咔啉 - Google Patents

用于治疗听力损伤和眩晕的β-咔啉 Download PDF

Info

Publication number
CN102844029A
CN102844029A CN2010800630256A CN201080063025A CN102844029A CN 102844029 A CN102844029 A CN 102844029A CN 2010800630256 A CN2010800630256 A CN 2010800630256A CN 201080063025 A CN201080063025 A CN 201080063025A CN 102844029 A CN102844029 A CN 102844029A
Authority
CN
China
Prior art keywords
cyclo
carboline
och
beta
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800630256A
Other languages
English (en)
Chinese (zh)
Inventor
H·罗美尔斯巴奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUDIOCURE PHARMA GmbH
Original Assignee
AUDIOCURE PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AUDIOCURE PHARMA GmbH filed Critical AUDIOCURE PHARMA GmbH
Publication of CN102844029A publication Critical patent/CN102844029A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800630256A 2009-12-28 2010-12-28 用于治疗听力损伤和眩晕的β-咔啉 Pending CN102844029A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102009060811.7 2009-12-28
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
US61/282,395 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
CN102844029A true CN102844029A (zh) 2012-12-26

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800630256A Pending CN102844029A (zh) 2009-12-28 2010-12-28 用于治疗听力损伤和眩晕的β-咔啉

Country Status (17)

Country Link
US (1) US9107914B2 (https=)
EP (1) EP2519238B1 (https=)
JP (1) JP5627705B2 (https=)
KR (1) KR20120098855A (https=)
CN (1) CN102844029A (https=)
AU (1) AU2010338669A1 (https=)
BR (1) BR112012015967B1 (https=)
CA (1) CA2785233C (https=)
DE (1) DE112010005017A5 (https=)
IL (1) IL220661A (https=)
IN (1) IN2012DN05066A (https=)
MX (1) MX2012007678A (https=)
NZ (1) NZ600478A (https=)
RU (1) RU2012132429A (https=)
SG (1) SG181599A1 (https=)
WO (1) WO2011079841A1 (https=)
ZA (1) ZA201204476B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579455A (zh) * 2013-09-29 2016-05-11 音频治疗制药有限公司 氟-9-甲基-β-咔啉
CN109963850A (zh) * 2016-11-14 2019-07-02 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 基因毒性应激诱导性IKK/NF-κB途径的选择性抑制剂

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120863B (zh) * 2013-03-14 2021-06-04 奥斯特克有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
LT2970890T (lt) 2013-03-14 2020-07-10 The Brigham And Women`S Hospital, Inc. Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
CA3109104A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Fluoro .beta.-carboline compounds
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2019339352B2 (en) 2018-09-12 2025-05-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
EP3772515A1 (en) 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308632A (zh) * 1998-06-12 2001-08-15 研究及应用科学协会股份有限公司 β－咔啉化合物
WO2008104161A1 (de) * 2007-02-26 2008-09-04 Ellneuroxx Ltd. ß-CARBOLINE ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308632A (zh) * 1998-06-12 2001-08-15 研究及应用科学协会股份有限公司 β－咔啉化合物
WO2008104161A1 (de) * 2007-02-26 2008-09-04 Ellneuroxx Ltd. ß-CARBOLINE ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG XING QUN，ET AL: "Neurotrophic Factors in the Auditory Periphery", 《ANNALS OF THE NEW YORK ACADEMY OF SCIENCES》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579455A (zh) * 2013-09-29 2016-05-11 音频治疗制药有限公司 氟-9-甲基-β-咔啉
CN105579455B (zh) * 2013-09-29 2017-07-28 音频治疗制药有限公司 氟‑9‑甲基‑β‑咔啉
CN109963850A (zh) * 2016-11-14 2019-07-02 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 基因毒性应激诱导性IKK/NF-κB途径的选择性抑制剂

Also Published As

Publication number Publication date
CA2785233A1 (en) 2011-06-07
IL220661A (en) 2016-03-31
SG181599A1 (en) 2012-07-30
AU2010338669A1 (en) 2012-06-21
ZA201204476B (en) 2014-01-29
US9107914B2 (en) 2015-08-18
JP2013515752A (ja) 2013-05-09
DE112010005017A5 (de) 2012-10-04
IL220661A0 (en) 2012-08-30
US20130028958A1 (en) 2013-01-31
JP5627705B2 (ja) 2014-11-19
RU2012132429A (ru) 2014-02-10
EP2519238B1 (de) 2014-08-13
EP2519238A1 (de) 2012-11-07
MX2012007678A (es) 2012-09-12
IN2012DN05066A (https=) 2015-10-09
BR112012015967B1 (pt) 2019-08-27
CA2785233C (en) 2018-10-09
WO2011079841A1 (de) 2011-07-07
BR112012015967A2 (pt) 2016-04-19
KR20120098855A (ko) 2012-09-05
NZ600478A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
CN102844029A (zh) 用于治疗听力损伤和眩晕的β-咔啉
ES2248950T3 (es) Utilizacion de cuatro derivados de k-252a.
EP1244670B1 (en) Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
AU2014326708B2 (en) Fluor-9-methyl-beta-carbolines
JP2003533541A5 (https=)
CN118974053A (zh) 作为金黄色葡萄球菌抑制剂的1H-吡唑并[4,3-d]嘧啶衍生物
JPWO2007046456A1 (ja) 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤
CN114945577B (zh) 大环内酯化合物及其治疗慢性呼吸道疾病的用途
WO2009110526A1 (ja) ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
HK1222844B (en) FLUOR-9-METHY-β-CARBOLINES
CA3198475A1 (en) Novel compound, preparation method thereof, and antibiotic composition comprising same
US20110319463A1 (en) Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
HK1164884A (en) Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121226